Utah-based Civica will begin selling a type of long-acting insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s Petersburg facility. Civica announced Thursday it has ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. U.S. regulators took action Wednesday that ...

LEHI, Utah, Oct. 16, 2025 /PRNewswire/ -- Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price ...

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...

On February 14, 2025, the U.S. Food and Drug Administration (“FDA”) approved Sanofi-Aventis U.S. LLC’s (“Sanofi”) MERILOG™ (insulin-aspart-szjj), a biosimilar to Novo Nordisk A/S’s (“Novo Nordisk”) ...

California Gov. Gavin Newsom announces CalRx-branded insulin glargine pens available beginning Jan. 1, 2026, at a suggested retail price of no more than $55 per five-pack, or $11 per pen, during a ...

California will begin selling long-acting, low-cost insulin in January, becoming the first state to bypass major pharmaceutical companies, Gov. Gavin Newsom (D-CA) announced Thursday. The move marks a ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for treating adults and children with diabetes. The approval ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog (insulin aspart). This new ...